Jianpi Fuzheng Decoction in the Treatment of Gastric Cancer-Related Fatigue

Objective:To observe the clinical effects of Jianpi Fuzheng Decoction in patients with gastric cancer and cancer-related fatigue(CRF).Methods:Using the random number table method as a reference,68 cases of gastric CRF were randomly divided into two groups.One group served as the control group and received basic treatment,while the other was the observation group.The observation group,in addition to the control group’s treatment,received Jianpi Fuzheng Decoction.The clinical treatment effectiveness,fatigue scores,immune function indicators,and treatment safety were compared between the two groups.Results:The total clinical treatment effectiveness of the observation group and the improvement in immune function indicators after treatment were higher than those of the control group.The fatigue score after treatment was lower in the observation group than in the control group(P<0.05).No serious adverse reactions occurred during the treatment in either group.Conclusion:Jianpi Fuzheng Decoction can enhance the clinical treatment effectiveness for gastric cancer patients with CRF.It facilitates the acceleration of fatigue symptom improvement and immune function enhancement.The medication’s safety is guaranteed,making it worthy of promotion.

Expression of phosphatase and tensin homolog deleted on chromosome ten in liver of athymic mice with hepatocellular carcinoma and the effect of Fuzheng Jiedu Decoction

AIM： To explore the expression of phosphatase and tensin homolog deleted on chromosome ten （PTEN） in liver of athymic mice with hepatocellular carcinoma （HCC） and the effect of Fuzheng Jiedu Decoction （FJD）. METHODS： Forty eight male BALB/c athymic mice models were built by Bel-7402 with an indirect method. After 24 h of postoperation, the 48 athymic mice were distributed randomly into 4 groups： A, B, C, D, each group had 12 athymic mice. Group A were were treated by intragastric administration with FT207 （Tegafur） for 4 wk. Group B, C and D were treated by intragastric administration with FJD （complex prescription of Chinese crude drug） that had been delegated into 3 kinds of density as the low, middle, and high for 4 wk. At last, athymic mice were put to death, live time, volume of tumors, exponent of tumors and the tumor metastasis in livers were observed; and PTEN was detected in hepatic tissue, latero-cancer tissue and cancer tissue by immunohistochemistry. RESULTS： Four weeks later, the total survival rate in treatment group （A ＋ B ＋ C） was 50% and higher than the control group （0%） treated by FT207, （P 〈 0.01）. The survival rate in group A, B, C was higher than in group D, and except group A with D, there was significant differentces （Fisher＇s Exact Test P = 0.05 or 0.01）. And no differences were observed between the treatment groups and the control group in volume of tumors and exponent of tumors （P 〉 0.05）. Tumor metastasis in livers of the treatment group was less than the controls （Fisher＇s Exact Test, P = 0.021）. The result of immunohistochemistry showed that the intensity of PTEN in latero-cancer tissue was the highest, and then the hepatic tissue, the lowest was cancer tissue （Kruskal- Wallis test, X^2 = 60.67, P = 0.000）. It also showed that the intensity of PTEN in treatment groups （A, B, C） was higher than the control group （D） （F = 5.90, P = 0.002 in hepatic tissue and F = 15.99, P = 0.000 in latero-cancer tissue and X^2 = 26.08, P = 0.000 in cancer tissue）, and group B is the highest in the treatment groups （P 〈 0.05, r = 0.01. respectively）. However, there was no significant statistic difference between group A and group C （P 〉 0.05）. CONCLUSION： FJD can prolong the survival time and decrease tumor metastasis in livers of these experimental mice. Mechanisms of FJD healing HCC may partially be explained by enhancing the expression of PTEN in liver.

Effect of Fuzheng Yiliu decoction combined with chemotherapy on patients with intermediate and late stage gastrointestinal cancer

AIM: To investigate the therapeutic effects of Fuzheng Yiliu (strengthening the body resistance to inhibit tumor) decoction combined with chemotherapy on the patients with intermediate and late stage gastrointestinal cancer. METHODS: Sixty patients were randomly divided into treatment group (chemotherapy combined with Fuzheng Yiliu decoction) and control group (chemotherapy alone). Four indexes, including the tumor recent remission rate (RR), the change of main symptoms, the toxic and side effects caused by chemotherapy and the change of performance status, were observed in the patients. Peripheral blood contents of CD3+, CD4+, CD8+ cells, CD4+/CD8+ and soluble interleukin-2 receptor (sIL-2R) were tested before and after treatment and the values were compared with those of healthy peoples. RESULTS: The improving rate of main symptoms (69.6%) and performance status (56.7%) were significantly higher in the treatment group than in the control group (34.8%, 26.7%, P<0.05). The occurrence rates of grade II toxic and side-effects on both bone marrow (13.3%) and digestive tract (30%) were lower in the treatment group compared to the control group (36.7%, 63.3%, P<0.05). Before treatment, the proportion of CD3+, CD4+ and CD4+/CD8+ decreased and the proportion of CD8+ and SIL-2R raised markedly both in the control group and treatment group as compared to the healttiy people. After treatment, that increased of CD3+, CD4+, CD4+/CD8+ increased (62.25±10.01% vs 68.31±9.72%, 36.83±10.44% vs 42.6±9.62%, 1.24±0.65 vs l.66±0.85, P<0.05) and the values of CD8+ and sIL-2R decreased obviously (33.06±7.69% vs 29.24±6.25%, 588.23±216.86 U/mL vs 475.87±211.36 U/mL,P<0.05) in the treatment group, whereas these values were opposite in the control group (64.22±6.91% vs60.63±5.75%,35.62±7.49% vs31.53±5.53%, 32.95±8.28% vs 37.14±7.48%, 1.17±0.43 vs 0.94±0.43, 573.63±214.32 U/mL vs 692.17?21.33 U/mL, P<0.05). CONCLUSION: Fuzheng Yiliu decoction can enhance therapeutic effects of chemotherapy on malignant gastrointestinal tumor, and also reduce the toxic and side effects on bone marrow and digestive tract, thereby improving the quality of life and cellular immunity in patients with malignant gastrointestinal tumor.

Intervention and immune regulation of Fuzheng Xiaoying Decoction on experimental autoimmune thyroiditis model rats

Objective:To investigate the effect of Fuzheng Xiaoying Decoction on experimental autoimmune thyroiditis(EAT)model rats and explore its possible mechanism of immune regulation.Methods:Among the 40 female SD rats,10 were randomly selected as the blank group,and the rest were immunized with pig thyroglobulin and Freund's adjuvant combined with high iodine feeding to make the EAT model.After the model was established,they were randomly divided into three groups:the model group,the selenium yeast tablet group and the Fuzheng Xiaoying Decoction group,which were continuously gavaged for 2 months.The anti thyroid autoantibodies,thyroid function,IL-38 and Th17/Treg distribution were measured.The pathological changes of thyroid tissue were observed by HE staining.Results:Compared with the blank group,the levels of TPOAb and TGAb in the model group were significantly higher(P<0.05).Lymphocyte infiltration was seen in the thyroid tissue of the model group,and also the thyroid follicles were partially destroyed,the shape was irregular,and the colloid distribution was uneven,indicating that the modeling was successful.Compared with the model group,the levels of TPOAb and TGAb in the selenium yeast tablet group and the Fuzheng Xiaoying Decoction group decreased significantly(P<0.05).And the Fuzheng Xiaoying Decoction group had more significant improvement in thyroid follicle destruction and lymphocyte infiltration than the selenium yeast tablet group(P<0.05).Compared with the blank group,the levels of T3,T4,FT3 and FT4 in the model group increased,the level of IL-38 decreased,the proportion of Th17 increased,and the ratio of Th17/Treg increased(P<0.05).Compared with the model group,T4 level decreased,IL-38 level increased in the selenium yeast tablet group and the Fuzheng Xiaoying Decoction group(P<0.05).But there was no statistically significant difference in the reduction of Th17 proportion and Th17/Treg ratio between the above two groups and the model group(P>0.05).There was no significant difference in Treg ratio among the groups.Conclusion:Fuzheng Xiaoying Decoction can significantly reduce the level of anti thyroid autoantibodies in EAT rats by regulating the immunity of EAT rats,and improve the follicular destruction and lymphocyte infiltration of thyroid tissue in rats.

Molecular mechanism prediction analysis of Xiaozheng decoction in the treatment of bladder cancer based on network pharmacology

Background:To investigate the mechanism of Xiaozheng decoction in treatment of bladder cancer based on network pharmacology.Methods:Based on the Tradictional Chinese Medicine Systems Pharmacology Database(TCMSP),the active compositions of Xiaozheng decoction were screened.The targets of active components were obtained from TCMSP,Swiss Target Prediction,and STITCH database.By mapping the disease targets of bladder cancer obtained from the DisGeNET and Genecards databases,the potential targets of Xiaozheng decoction for bladder cancer were obtained.The active components of Xiaozheng decoction-targets network was constructed using the Cytoscape software.The target protein interaction(PPI)network was constructed by using the String online platform,which was visualized by Cytoscape software and analyzed by network topology to obtain the key targets of Xiaozheng decoction.GO bioprocess enrichment analysis and KEGG pathway enrichment analysis were performed on key targets of the Xiaozheng decoction by DAVID database.Results:A total of 68 active components and 255 potential targets of Xiaozheng decoction in the treatment of bladder cancer were retrieved and screened out.The key targets were enriched and analyzed by the GO biological pathway,and 135 pathways were obtained,which involved transcriptional process,platelet activation,cell proliferation,and apoptosis.KEGG pathway enrichment analysis revealed 95 pathways,mainly involving cancer pathway,bladder cancer pathway,MAPK signaling pathway,PI3K-Akt signaling pathway,and VEGF signaling pathway.Conclusion:The result of this study showed that Xiaozheng decoction may play its therapeutic role through multiple components,multiple targets and multiple pathways,and preliminarily explored the mechanism of Xiaozheng decoction in the treatment of bladder cancer,laying a foundation for subsequent experimental studies.

Clinical Observation of Zhuang Medicine Yangxue Xiaozheng Decoction in Treating the Combined Endometriosis of Dampness and Blood Stasis in Guangxi

Objective:To explore the clinical effects of Zhuang Medicine Yangxue Xiaozheng Decoction in treating the combined Ems of dampness and blood stasis in Guangxi;Methods:100 patients with endometriosis treated in Lili Clinic of Famous Doctor,Guangxi International Zhuang Medicine Hospital from Mach 2016 to May 2017 were chosen as the research object.According to the random grouping method,patients were randomly divided into the treatment group(The Zhuang Medicine Yangxue Xiaozheng Decoction(ZYF)Group)and the control group(Chinese patent medicine SanJieZhenTongJiaoNang(SJZT)group with 50 cases in each group.After treatment,the TCM syndrome score,changes in pelvic mass size,hepatocyte growth factor(HGP)levels,and clinical effects before and after treatment were evaluated.Results:After two courses of treatment,the total effective rate of patients in the ZYF group was 88%,which were significantly better than 70%of the SJZT group.The difference was statistically significant(P<0.05).Conclusion:With a significant effect on patients with the combined Ems of dampness and blood stasis in Guangxi,Zhuang Medicine Yangxue Xiaozheng Decoction can improve the uterine cavity mass and reduce serum HGP level.

扶正化浊汤联合甲状腺片治疗对甲状腺结节大小及疗效的影响

目的探讨扶正化浊汤治疗甲状腺结节(TN)对结节大小的影响。方法TN患者106例,随机均分为观察组和对照组,对照组给予左甲状腺素钠片常规治疗,观察组在对照组基础上同时增加扶正化浊汤治疗;于治疗前、治疗3个月时,对2组患者进行中医主症评分,采用彩色多普勒超声仪记录2组患者结节数目、最大直径、结节体积、血流阻力指数(RI)及搏动指数(PI),同时采集患者外周静脉血4 mL,检测促甲状腺激素(TSH)、游离三碘甲状腺原氨酸(FT3)、游离四碘甲腺原氨酸(FT4)及血管内皮生长因子(VEGF)水平,治疗3个月后评估2组患者的西医疗效,记录2组治疗期间恶心、呕吐、皮疹及口干等不良反应发生情况。结果治疗后3个月,2组中医主症评分均较治疗前下降,且观察组低于对照组(P<0.05);与对照组比较,2组TN患者治疗3个月后结节数目减少、结节最大直径和结节体积均降低,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后3个月,观察组TSH低于对照组,FT 3、FT 4高于对照组(P<0.05);治疗3个月后,观察组VEGF、RI、PI低于对照组(P<0.05);观察组西医疗效和中医证候疗效中的临床痊愈和总有效率均高于对照组,差异有统计学意义(P<0.05);比较观察组与对照组不良反应发生率比较,差异无统计学意义(P>0.05)。结论扶正化浊汤治疗TN疗效显著,可有效减轻患者症状,减小结节数目及大小,调节甲状腺功能,改善血流状况,降低VEGF表达,且安全性高。

加味消癥方对慢性肾衰竭大鼠肾纤维化的保护作用及对肾小管上皮细胞TGF-β_(1)/Smad3信号通路的影响

目的:探讨加味消癥方对慢性肾衰竭大鼠肾纤维化的保护作用及对肾小管上皮细胞TGF-β_(1)/Smad3信号通路的作用影响。方法:观察加味消癥方对慢性肾衰竭大鼠的血肌酐、尿素氮、24 h尿蛋白定量、肾脏病理及肾组织中FN1、Col-Ⅰ、Col-Ⅲ表达水平的影响;观察加味消癥方对TGF-β_(1)诱导肾小管细胞损伤中TGF-β_(1)、Smad3、LC3、Beclin1及P62蛋白表达的影响。结果:与模型组相比,加味消癥方高剂量组的Scr水平及加味消癥各组和缬沙坦组的24 h尿蛋白水平显著降低(P<0.05,P<0.01);实时荧光定量PCR法检测提示加味消癥方高剂量组的FN1、Col-ⅠmRNA相对表达量、加味消癥方中剂量组和缬沙坦组的Col-ⅢmRNA相对表达量、高剂量组和缬沙坦组的TGF-β_(1)mRNA相对表达量以及高、中、低剂量组和缬沙坦组的Smad3 mRNA相对表达量均较模型组显著降低(P<0.05,P<0.01);Western Blot法检测提示加味消癥方高、中剂量组和缬沙坦组的FN蛋白表达量、加味消癥方高剂量组的Col-Ⅰ蛋白表达量、加味消癥方高、低剂量组和缬沙坦组的Col-Ⅲ蛋白表达量以及高、中剂量组的Beclin1蛋白表达量均较模型组显著降低(P<0.05,P<0.01);Masson染色观察加味消癥方高剂量组的肾间质纤维化程度显著减轻(P<0.01)。此外,该组的48 h/72 h细胞存活率显著升高(P<0.01)。结论:加味消癥方可有效提升细胞存活率,改善肾间质纤维化程度保护肾功能,可能是通过TGF-β_(1)/Smad3通路调控自噬水平,下调FN1、Col-Ⅰ、Col-Ⅲ水平实现的。

参芪扶正汤治疗桥本氏甲状腺炎合并甲状腺功能减退临床疗效及相关机制研究

[目的]探讨参芪扶正汤治疗桥本氏甲状腺炎(HT)合并甲状腺功能减退的临床疗效,初步分析其治疗机制。[方法]选择秦皇岛市中医医院2020年1月—2023年1月收治的HT患者110例,按照随机数字表法分为观察组和对照组,每组55例,两组均口服左甲状腺素钠片,在此基础上,对照组口服亚硒酸钠片,观察组口服中药参芪扶正汤,疗程12周。比较两组治疗前后中医证候评分、甲状腺体积和峡部厚度、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺素(TSH)、甲状腺球蛋白抗体(TGAb)、甲状腺过氧化物酶抗体(TPOAb),长链非编码RNA人母系表达基因3(lncRNA MEG3)、微小RNA-17(miR-17)、辅助性T淋巴细胞亚群17(Th17)、调节性T细胞(Treg)含量、Th17/Treg值,并比较两组治疗总有效率。[结果]治疗后观察组中医证候评分低于对照组(P<0.05),甲状腺体积和峡部厚度均低于对照组(P<0.05);血清FT3、FT4水平高于对照组(P<0.05),TSH、TGAb、TPOAb水平低于对照组(P<0.05);观察组Th17、Th17/Treg、miR-17低于对照组(P<0.05),Treg、lncRNA MEG3高于对照组(P<0.05);治疗总有效率高于对照组(P<0.05)。[结论]参芪扶正汤可以改善中医证候和甲状腺功能,调节甲状腺自身抗体,减小甲状腺体积,治疗HT合并甲状腺功能减退效果显著,其机制可能与调节血清lncRNA MEG3、miR-17有关。

通络扶正汤对脑卒中后遗症患者血清Wnt3a、Wnt5a表达量及神经功能影响分析

【目的】分析通络扶正汤(由胆南星、法半夏、桃仁、天麻、全蝎、红花、地龙等中药组成)对脑卒中后遗症患者神经功能及血清分泌型糖蛋白(Wnt)3a、Wnt5a表达量的影响。【方法】采用回顾性研究方法,根据治疗方案的不同将146例脑卒中后遗症风痰瘀阻证患者分为观察组和对照组,每组各73例。对照组给予常规西药及康复治疗,观察组在对照组的基础上给予通络扶正汤治疗,疗程为3周。观察2组患者治疗前后美国国立卫生研究院卒中量表(NIHSS)评分、Berg平衡量表(BBS)评分、Fugl-Meyer量表(FMA)评分、Holden步行功能分级(FAC)、躯干屈伸肌群表面肌电均方根值(RMS)及血清Wnt3a、Wnt5a表达量的变化情况,并比较2组患者的临床疗效和不良反应发生率。【结果】(1)治疗3周后,观察组的总有效率为95.89%(70/73),对照组为79.45%(58/73),组间比较,观察组的疗效明显优于对照组(P<0.01)。(2)治疗后,2组患者的NIHSS评分均较治疗前明显降低(P<0.05),BBS、FMA评分均较治疗前明显升高(P<0.05),且观察组对NIHSS评分的降低幅度及对BBS、FMA评分的升高幅度均明显优于对照组(P<0.01)。(3)治疗后,2组患者的FAC分级均较治疗前改善(P<0.05),且观察组对FAC分级的改善作用明显优于对照组(P<0.05)。(4)治疗后,2组患者的竖脊肌、腹直肌表面肌电RMS值均较治疗前明显升高(P<0.05),且观察组对竖脊肌、腹直肌表面肌电RMS值的升高幅度均明显优于对照组(P<0.01)。(5)治疗后,2组患者的血清Wnt3a、Wnt5a表达量均较治疗前明显升高(P<0.05),且观察组对血清Wnt3a、Wnt5a表达量的升高幅度均明显优于对照组(P<0.01)。(6)观察组的不良反应发生率为4.11%(3/73),对照组为6.85%(5/73),组间比较,差异无统计学意义(P>0.05)。【结论】通络扶正汤可有效减轻脑卒中后遗症患者神经功能受损程度及运动障碍,提高平衡能力及治疗效果,增强躯干屈伸肌群肌力,上调血清Wnt3a、Wnt5a表达量,且不良反应发生率低,具有较高的安全性。

扶正解毒汤对结直肠癌患者的作用效果

目的研究扶正解毒汤对结直肠癌患者的作用效果。方法选取2020年1月至2022年10月河南中医药大学第三附属医院收治的96例结直肠癌患者,根据简单随机分组法分为化疗组(48例)和扶正解毒组(48例)。化疗组接受FOLFOX4化疗方案治疗,扶正解毒组在化疗组的基础上接受扶正解毒汤治疗,两组均治疗18周。统计两组治疗18周后的临床疗效,比较两组治疗前和治疗18周后中医证候积分、功能状态、肿瘤标志物、磷脂酰肌醇3酶-丝苏氨酸蛋白激酶(PI3K-Akt)信号通路、肠道菌群、生活质量。结果治疗18周后,扶正解毒组疾病控制率及总缓解率(68.75%、54.17%)高于化疗组(47.92%、31.25%)(P<0.05)。治疗18周后扶正解毒组主症、次症评分与治疗前比较降低,且低于化疗组(P<0.05);与治疗前比较,两组功能状态评分、乳酸杆菌、双歧杆菌数量及未来展望评分升高,且扶正解毒组高于化疗组(P<0.05);与治疗前比较两组血清癌胚抗原、糖类抗原199、外周血PI3K mRNA、Akt mRNA水平、肠球菌、大肠杆菌数量及排尿便问题、体重下降评分降低,且扶正解毒组低于化疗组(P<0.05)。结论扶正解毒汤联合FOLFOX4化疗方案可改善结直肠癌患者中医证候、功能状态,降低肿瘤标志物水平,调节PI3K-Akt信号通路、肠道菌群,提高患者生活质量,具有较好的治疗效果。

扶正消瘿汤联合左甲状腺素钠片治疗桥本甲状腺炎疗效及对血清炎症因子的影响

目的:观察扶正消瘿汤联合左甲状腺素钠片治疗桥本甲状腺炎(HT)的疗效及对血清炎症因子的影响。方法:选取90例HT患者,按随机数字表法分为观察组及对照组各45例。对照组服用左甲状腺素钠片治疗,观察组在对照组基础上加用扶正消瘿汤。比较2组临床疗效及不良反应发生情况,比较2组治疗前后中医证候积分、甲状腺体积、实验室检查指标[白细胞介素-6(IL-6)、白细胞介素-12(IL-12)、肿瘤坏死因子-α(TNF-α)、游离三/四碘甲状腺原氨酸(FT_(3)/FT_(4))、促甲状腺激素(TSH)、过氧化物酶抗体(TPOAb)、球蛋白抗体(TGAb)]值的变化。结果:治疗后,2组中医证候积分均较治疗前下降(P<0.05),观察组中医证候积分低于对照组(P<0.05)。观察组临床疗效总有效率为93.33%,对照组临床总有效率为75.56%,2组临床疗效比较,差异有统计学意义(P<0.05)。治疗后,2组甲状腺体积均较治疗前缩小(P<0.05),观察组甲状腺体积小于对照组(P<0.05)。治疗后,2组IL-6、IL-12、TNF-α、TSH、TPOAb、TGAb水平均较治疗前下降(P<0.05),FT_(3)、FT_(4)水平均较治疗前上升(P<0.05);观察组IL-6、IL-12、TNF-α、TSH、TPOAb、TGAb水平均低于对照组(P<0.05),FT_(3)、FT_(4)水平均高于对照组(P<0.05)。治疗期间,2组患者出现不良反应经休息后,均自行恢复。结论:扶正消瘿汤联合左甲状腺素钠片治疗HT能有效提高临床疗效,抑制血清炎症因子水平,降低炎症反应,缓解临床症状。

消癥汤联合米非司酮对子宫肌瘤患者血清肿瘤标志物及肿瘤相关因子水平的影响

目的探讨消癥汤联合米非司酮对子宫肌瘤患者血清肿瘤标志物及肿瘤相关因子水平的影响。方法选取首都医科大学附属北京同仁医院2019年12月至2022年12月收治的子宫肌瘤患者120例,按治疗方案的不同分为观察组和对照组,各60例。两组患者均予米非司酮片口服,观察组患者加服消癥汤。两组均持续治疗14周。结果观察组总有效率为98.33%,显著高于对照组的85.00%(P<0.05)。两组患者治疗后的子宫体积及子宫肌瘤体积较治疗前显著缩小(P<0.05),血清肿瘤标志物(糖类抗原125、人附睾分泌蛋白4)、雌激素、肿瘤相关因子(血管内皮生长因子、γ干扰素、肿瘤坏死因子-α、基质金属蛋白酶-9)水平均较治疗前显著降低(P<0.05);且观察组上述指标改善幅度均显著大于对照组(P<0.05)。观察组与对照组的不良反应发生率无显著差异(5.00%比10.00%,P>0.05)。结论消癥汤联合米非司酮治疗子宫肌瘤,可降低患者血清肿瘤标志物及肿瘤相关因子水平,缩小子宫肌瘤体积。

扶正透邪解毒化瘀方对多重耐药铜绿假单胞菌肺炎老年大鼠炎症损伤的影响

目的探讨扶正透邪解毒化瘀方对多重耐药铜绿假单胞菌(MDRPA)肺炎老年大鼠不同时相炎症损伤的影响。方法将老年SD大鼠分为空白组、模型组、西药组、中药组、中药提前给药组、中西医结合治疗组,除空白组外使用经口气管插管法进行MDRPA肺炎造模,观察各组大鼠死亡保护率、生命延长率;在感染后不同时间点取大鼠血清及肺组织标本,应用ELISA试剂盒测定血清肿瘤坏死因子-α(TNF-α)、白细胞介素-10(IL-10)水平,光镜下观察肺组织支气管、肺泡等结构;在感染后第3日取肺组织标本,电镜下观察各组肺组织超微结构。结果中药提前给药组和中西医结合治疗组可提高死亡保护率和生命延长率。中西医结合治疗组可明显降低MDRPA肺炎老年大鼠血清中促炎因子TNF-α水平,升高抑炎因子IL-10水平,其作用强度明显优于西药组,且可明显减少肺组织炎症细胞浸润和充血水肿,明显减轻肺泡结构的破坏。中药提前给药组可在炎症反应早期升高血清抑炎因子IL-10水平,降低促炎因子TNF-α水平。结论扶正透邪解毒化瘀方对老年MDRPA肺炎大鼠有着较高的死亡保护率和生命延长率,与头孢他啶联合治疗可纠正MDRPA感染后紊乱的炎症状态,减轻炎症损伤。中药提前给药可对MDRPA感染后造成的炎症损伤起到保护与治疗作用,对维持机体免疫稳态具有重要意义。

扶正安中汤联合索拉非尼在中晚期肝癌患者的临床观察

目的:探讨扶正安中汤联合索拉非尼(SOR)治疗肝动脉插管化疗栓塞术(TACE)后中晚期肝细胞癌(HCC)患者的临床效果。方法:选取2021年1至12月亳州市中医院肿瘤科收治的TACE后的中晚期HCC患者100例作为研究对象,用简单随机化分组方法分为对照组和观察组,每组50例。对照组采用SOR治疗,观察组采用SOR联合扶正安中汤治疗,持续治疗3个疗程后予以疗效评估,随访1年;比较2组治疗前后中医证候积分、肝功能、肾功能、肿瘤标志物及炎症介质水平指标;统计1年患者生存情况及用药安全性。结果:对照组和观察组疾病控制率分别为24.00%和56.00%(P<0.05)。治疗后,2组患者中医证候积分、血清指标谷草转氨酶(GOT)、谷丙转氨酶(GPT)、白蛋白(ALB)、总胆红素(TB)较治疗前下降,且对照组高于观察组(均P<0.05);2组患者血清肌酐(Cr)、尿素氮(BUN)较治疗前升高,且对照组低于观察组,但差异无统计学意义(P>0.05)。1年随访期间对照组和观察组生存率分别为24.00%和42.00%,组间差异显著(χ~2=8.72,P=0.0018)。2组血清恶性肿瘤特异性生长因子(TSGF)、血清甲胎蛋白(AFP)、血管内皮生长因子(VEGF)、肿瘤坏死因子-α(TNF-α)及白细胞介素-6(IL-6)水平较治疗前下降,且对照组高于观察组(P<0.05)。结论:扶正安中汤联合SOR是治疗TACE后中晚期HCC患者的有效方案。相对于单独使用SOR治疗,能有效调节血清肿瘤标志物及炎症介质水平,且不增加药物治疗风险。

胃癌相关肌少症的CT评估及中医疗效观察

目的:观察健脾养正消癥方联合化疗治疗胃癌相关肌少症的临床疗效。方法:选择105例胃癌患者,随机分为试验组54例和对照组51例,2组均采用标准化疗方案治疗24周,试验组同时采用健脾养正消癥方联合治疗。结果:试验组治疗后平均骨骼肌面积减少率小于对照组(P<0.001);2组炎症标志物白介素-6(IL-6)、白介素-4(IL-4)均下降,其中治疗组下降更显著,与对照组差异均有统计学意义(均P<0.001)。结论:健脾养正消癥方治疗胃癌相关肌少症能延缓患者肌肉质量下降进程,降低体内炎症水平。

基于网络药理学和分子对接技术探讨扶正解毒方治疗社区获得性肺炎的作用机制

目的基于网络药理学和分子对接技术探讨扶正解毒方治疗社区获得性肺炎(CAP)可能的作用机制。方法应用TCMSP、UniPort数据库筛选扶正解毒方的药物活性成分及相对应的靶点蛋白;应用GeneCards、OMIM和Disgent数据库中检索出CAP相关靶基因。应用Metascape数据库进行GO富集分析和KEGG通路富集分析;最后通过CB-Dock对网络中度值较高的药物成分与核心作用靶点进行分子对接验证。结果筛选得到扶正解毒方治疗CAP重要活性成分215个,核心靶点113个,确定扶正解毒方治疗CAP的主要通路,分子对接中活性成分与靶点具有较为稳定的结合活性。结论扶正解毒方具有多因素协同调控的作用特点,这为进一步阐明扶正解毒方治疗CAP的作用机制提供了科学思路与依据。

扶正升白汤对小细胞肺癌化疗后白细胞减少症患者的影响

目的:探讨扶正升白汤对小细胞肺癌化疗后白细胞减少症患者白细胞计数、卡诺夫斯凯计分(KPS)的影响。方法:选取2020年1月至2021年3月河北中医药大学附属沧州中西医结合医院收治的需进行化疗的小细胞肺癌患者(化疗后白细胞减少)120例为研究对象,通过随机数字表法分为观察组(60例,皮下注射重组人粒细胞集落刺激因子+扶正升白汤)和对照组(60例,皮下注射重组人粒细胞集落刺激因子)。比较两组患者的临床疗效、中医证候积分、白细胞计数、中性粒细胞绝对值和KPS评分。结果:观察组患者的总有效率为88.33%(53/60),高于对照组的70.00%(42/60),差异有统计学意义(P<0.05)。与治疗前相比,两组患者治疗后中医证候积分降低,白细胞计数、中性粒细胞绝对值升高,KPS评分升高;且观察组患者治疗后上述指标优于对照组,差异均有统计学意义(P<0.05)。结论:扶正升白汤能显著提高小细胞肺癌化疗后白细胞减少症患者的白细胞计数,改善临床症状,提高KPS评分。

扶正固表方对免疫低下小鼠免疫功能的实验研究

[目的]研究扶正固表方对环磷酰胺诱导免疫低下小鼠的免疫调节作用。[方法]48只Balb/c小鼠随机分为对照组、模型组、扶正固表方组(7.15 g/kg)和西药组(盐酸左旋咪唑,30 mg/kg),除对照组外,其他各组小鼠腹腔注射环磷酰胺制备免疫低下小鼠模型。造模成功后,扶正固表方组和西药组分别给予灌胃干预7 d。观察各组小鼠的一般状态和体质量变化,检测免疫器官指数;酶联免疫吸附法测定血清肿瘤坏死因子-α(TNF-α)、白介素-4(IL-4)和干扰素-γ(IFN-γ)的水平;苏木素-伊红染色法观察脾脏病理变化;流式细胞术检测脾淋巴细胞亚群CD4+T淋巴细胞、CD8+T淋巴细胞及CD4+/CD8+的分布与比例;实时荧光定量聚合酶链反应法与蛋白免疫印迹法检测脾脏组织中NF-κB p65和IκBαmRNA与蛋白的表达水平。[结果]与对照组相比,模型组小鼠出现精神萎靡,毛发黯淡等体征,伴随体质量、脾脏指数和胸腺指数降低(P<0.01);血清TNF-α水平升高(P<0.01),而IL-4和IFN-γ水平降低(P<0.01);脾组织红、白髓界限不清,伴有红细胞和炎性细胞浸润;脾CD4+淋巴细胞数下降(P<0.01),CD8+淋巴细胞数升高(P<0.01),CD4+/CD8+比例降低(P<0.01);脾组织中NF-κB p65 mRNA与蛋白表达降低(P<0.01),IκBαmRNA和蛋白表达升高(P<0.01)。与模型组相比,扶正固表方组一般状态有所改善,体质量升高,脾脏指数和胸腺指数提升(P<0.01),血清TNF-α水平降低(P<0.01),IL-4和IFN-γ水平升高(P<0.01),脾组织红、白髓界线逐渐清晰,脾CD4+淋巴细胞数增多,CD8+淋巴细胞数降低,CD4+/CD8+比例上升;脾组织中NF-κB p65 mRNA与蛋白的表达水平上升(P<0.05),IκBαmRNA和蛋白表达降低(P<0.05)。[结论]扶正固表方可以调节免疫低下小鼠的免疫状态,增强机体的免疫功能。

恩替卡韦联合扶正解毒散结方治疗乙型肝炎肝硬化患者疗效研究

目的探讨应用恩替卡韦联合扶正解毒散结方治疗乙型肝炎肝硬化患者的疗效。方法2020年9月~2022年9月我院诊治的乙型肝炎肝硬化患者112例,被随机分为对照组56例和观察组56例,分别给予恩替卡韦或恩替卡韦联合扶正解毒散结方治疗24 w。采用放射免疫分析法检测血清Ⅲ型前胶原(PC-Ⅲ)、层粘连蛋白(LN)、透明质酸(HA)和Ⅳ型胶原(Ⅳ-C),使用彩色多普勒超声诊断仪检测脾脏厚度、脾静脉内径和门静脉内径,使用肝脏瞬时弹性检测仪行肝脏硬度检测(LSM)。结果在治疗24 w末,观察组ALT复常率为92.9%,显著高于对照组的75.0%(P<0.05);观察组胁下积块、腹大坚满、胁痛如刺、面色晦黯、纳呆、口干苦和便溏等中医证候积分分别为(1.0±0.2)分、(1.2±0.3)分、(1.0±0.2)分、(0.9±0.2)分、(0.8±0.2)分、(0.9±0.2)分和(0.7±0.1)分,均显著低于对照组【分别为(1.5±0.3)分、(1.7±0.4)分、(1.6±0.3)分、(1.5±0.2)分、(1.2±0.3)分、(1.4±0.3)分和(1.2±0.2)分,P<0.05】;观察组血清ALT水平为(41.6±9.0)U/L,显著低于对照组【(59.7±11.5)U/L,P<0.05】;观察组血清PC-Ⅲ和HA水平分别为(106.4±17.9)μg/L和(122.3±15.6)μg/L,均显著低于对照组【分别为(145.4±20.6)μg/L和(167.9±24.2)μg/L,P<0.05】;观察组脾脏厚度和LSM分别为(43.8±3.5)mm和(11.0±1.6)kPa,均显著低于对照组【分别为(46.4±4.0)mm和(13.3±2.1)kPa,P<0.05】。结论应用恩替卡韦联合扶正解毒散结方治疗乙型肝炎肝硬化患者能缓解临床症状,改善肝功能,抑制肝纤维化进展,值得临床进一步研究。